Acutaas Chemical (ACUTAAS)

FairStock Score: 53/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Acutaas Chemical as a businessman first, speculator second. The numbers show a fast-growing pharmaceutical business: sales up 47.25%, profits up 69.99%, and a five-year revenue CAGR of 33.22%. Latest quarter sales were ₹393 Cr with net profit ₹106 Cr, implying roughly 27% net margin. Return on equity is 24.26% and ROCE is 19.92%, while debt/equity is only 0.02, so the balance sheet is conservatively financed. Piotroski F-score 7/9 supports improving fundamentals, and PEG of 0.67 suggests growth may be under-priced relative to the P/E. But Benjamin Graham would stop at the price: ₹3235.60, market cap ₹26,490 Cr, P/E 92.60 and P/B 16.02 against book value ₹201.93. That is not a bargain; it embeds high expectations. Free cash flow is negative ₹106 Cr, so reported profits are not yet converting into owner cash. Dividend yield is 0.05%, giving almost no current return. Promoter holding is 32.66%, meaningful but not overwhelming. The 52-week range ₹1,467.50–₹3,735 shows severe volatility and momentum. FairStock score 53/100 mixed. My verdict: a high-quality growth candidate with a possible moat shown by high ROE/ROCE and low debt, but the margin of safety is thin. I would watch cash conversion, sales/profit durability, and valuation. I would not chase at 92 times earnings; I would wait for a price that lets me be wrong without permanent loss. Mr. Market is enthusiastic; I prefer patience.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer